Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Safety And FDA’s Centennial: As The Agency Turns 100, “Adulterated Drugs” Is Taking On A Whole New Meaning

You may also be interested in...

“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?

FDA is considering proactive communication of early adverse event reports from its MedWatch monitoring system as the agency reassesses its proposed Drug Watch website for emerging safety information

Follow-On Biologics Pathway Unlikely Without Confirmed FDA Commissioner

FDA is unlikely to proceed with developing a follow-on biologics pathway until a permanent commissioner is confirmed, a Senate Health Committee staffer said at a Food & Drug Law Institute conference in Washington, D.C., Nov. 16

Drugs Should Get Longer Patents In Exchange For More Safety Data – Wood

Offering extended exclusivity, in advance, for drugs that address an unmet medical need could bring a necessary boost to research and development efforts, Vanderbilt University's Alastair Wood said

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts